Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.43 |
| ▸ | RAMP3 | O60896 | 12/20 | 0.42 |
| ▸ | CALCR | P30988 | 12/20 | 0.42 |
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.41 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.41 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22018530 | 1.00 | APLNR (0.43) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018529 | 0.96 | NAA50 (0.44) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018354 | 0.95 | APLNR (0.46) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22019192 | 0.95 | APLNR (0.45) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018380 | 0.95 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018502 | 0.95 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018809 | 0.95 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018370 | 0.95 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018340 | 0.95 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL22018314 | 0.95 | APLNR (0.48) | APLNRRAMP3CALCRNMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | VIP, IAPP, NGLY1 | APLNR 334/4885RAMP3 1549/4885CALCR 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.